IL-17A (IL-17) is the first of a six-member family of cytokines (IL-17A--F). IL-17 is produced by NK and T cell subsets, including helper α/β T cells, γ/δ T cells, and NKT cells, and it binds to a widely expressed receptor ([@bib1]). This cytokine was first described 10 yr ago, but interest in this molecule was recently revived by the identification of a specific IL-17--producing T helper cell subset in the mouse ([@bib1]). The specific development and phenotype of IL-17--producing helper T cells have been characterized in the mouse model, in which these cells have clearly been identified as a Th17 subset. The hallmarks of mouse Th17 cells include (a) a pattern of cytokine production different from those of the Th1 and Th2 subsets, with high levels of IL-17 production, often accompanied by IL-17F and IL-22; (b) dependence on TGF-β and IL-6 for early differentiation from naive CD4 T cells, followed by dependence on IL-21 and IL-23 for further expansion; and (c) dependence on at least four transcription factors for differentiation: the Th17-specific retinoic acid receptor--related orphan receptor γt (RORγt) and RORα, and the more promiscuous STAT-3 and IFN regulatory factor 4 (for review see reference [@bib1]).

Increasingly detailed descriptions of the in vitro and in vivo differentiation of the Th17 subset in mice are becoming available. In contrast, the tremendous, uncontrolled genetic and epigenetic variability of human samples has made it difficult to characterize human IL-17--producing T cells ([@bib2]--[@bib13]). It has proved very difficult to identify the cytokines governing the differentiation of these cells in vitro. The first four groups that have investigated this issue all suggested that TGF-β was not required for the differentiation of human IL-17--producing T helper cells from purified naive CD4 T cells in vitro ([@bib5]--[@bib8]). TGF-β was even found to inhibit differentiation in three studies ([@bib5], [@bib6], [@bib8]). IL-6 was inhibitory in one study ([@bib6]) and redundant in three others ([@bib5], [@bib7], [@bib8]). In contrast, IL-23 was found to enhance the development of IL-17 T cells in all four studies ([@bib5]--[@bib8]) and IL-1β was identified as a positive regulator in two studies ([@bib5], [@bib6]), whereas IL-21, which was tested in one study, was found to be redundant ([@bib8]). In contrast, three recent studies showed that TGF-β is essential in this process, whereas there was more redundancy between the four ILs ([@bib11]--[@bib13]). In vitro studies using recombinant cytokines and blocking antibodies have therefore yielded apparently conflicting results, particularly if the results for human cells are compared with those for mice.

We used a novel approach to address this issue, making use of patients with various inborn errors of immunity impairing most of these cytokine signaling pathways separately to investigate the development of IL-17 T cells in vivo. We studied the following groups: (a) patients with autosomal-dominant developmental disorders associated with various mutations in the TGF-β pathway associated with enhanced TGF-β signaling, such as Camurati-Engelmann disease, with mutations in *TGFB1* ([@bib14]), or Marfan-like syndromes, with mutations in *TGFBR1* or *TGFBR2* ([@bib15]); (b) patients with autosomal-recessive susceptibility to pyogenic bacteria and loss-of-function mutations in *IRAK4* ([@bib16]) or *MYD88* (unpublished data), whose cells do not respond to IL-1β and related cytokines or to Toll-like receptors (TLRs) other than TLR3; (c) patients with autosomal-dominant hyper-IgE syndrome (AD-HIES) associated with dominant-negative mutations in *STAT3* ([@bib17], [@bib18]), whose cells respond poorly to several cytokines, including IL-6; and (d) patients with autosomal-recessive susceptibility to mycobacterial diseases and loss-of-function mutations in *IL12B* or *IL12RB1* ([@bib19]), whose cells do not express or do not respond to IL-12 and IL-23 (Table S1, available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>). The role of IL-21 cannot be studied in this way, as the only known defects in this pathway (i.e., JAK3 and common γ chain deficiencies) are typically associated with a total absence of T cells ([@bib20]).

RESULTS AND DISCUSSION
======================

We used flow cytometry to investigate the percentage of IL-17--expressing blood T cells ex vivo in 49 healthy controls. Nonadherent PBMCs were stained for CD3, CD4, CD8, and IL-17. No IL-17--producing T cells were detected in the absence of activation (unpublished data). Upon activation with PMA-ionomycin, the percentage of CD3-positive cells producing IL-17 ranged from 0.06 to 2% ([Fig. 1, A and B](#fig1){ref-type="fig"}). The vast majority (\>90%) of IL-17--positive cells were CD4-positive and CD8-negative (unpublished data). Thus, within the general population, there is considerable interindividual variability in the numbers of IL-17--producing cells present among freshly isolated T cells activated ex vivo. This makes it difficult to assess the impact of genetic lesions on the development of IL-17--producing T cells. We tested nine patients with null mutations in *IRAK4* or *MYD88*, whose cells were unresponsive to IL-1β (and most TLRs and other IL-1 cytokine family members). The proportion of IL-17--producing T cells was not significantly different from that in healthy controls, as shown by Wilcoxon tests comparing the values for each individual between the two groups ([Fig. 1, A and B](#fig1){ref-type="fig"}). We then tested 17 patients with null mutations in *IL12B* or *IL12RB1*, whose cells did not produce (for *IL12B* mutations) or did not respond (for *IL12RB1* mutations) to IL-23 (and IL-12). Interestingly, there were clearly fewer IL-17--producing T cells in these patients than in healthy controls (P = 4.7 × 10^−3^; [Fig. 1, A and B](#fig1){ref-type="fig"}). However, some patients had normal numbers of IL-17--producing T cells. In contrast, cells from patients with mildly enhanced TGF-β responses owing to mutations in *TGFB1* or *TGFBR2* did not differ significantly from controls ([Fig. 1 B](#fig1){ref-type="fig"}). These results suggest that IL-1R--associated kinase 4 (IRAK-4) and MyD88 are not required for the development of IL-17--producing T cells in vivo, that TGF-β probably does not markedly inhibit this process, and that both IL-12p40 and IL-12Rβ1 are required, at least in most individuals and in these experimental conditions of flow cytometry on T cells activated ex vivo.

![**Identification of IL-17--producing T cells ex vivo.** (A) Flow cytometry analysis of CD3 and IL-17 in nonadherent PBMCs activated with PMA-ionomycin as a representative control, an IRAK-4--deficient patient (P4), an IL-12Rβ1--deficient patient (P17), and a STAT-3--deficient patient (P36; Table S1, available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>). The percentage indicated in the gate is that of IL-17-- and CD3-positive cells. (B) Percentage of CD3-positive cells that were also IL-17--positive, as determined by flow cytometry of nonadherent PBMCs activated with PMA-ionomycin. Each symbol represents a value from an individual control (black circles) or patient (red circles). Horizontal bars represent medians. The p-values for Wilcoxon tests between controls (*n* = 49) and patients with mutations in *IRAK4* or *MYD88* (*n* = 9), *IL12B* or *IL12RB1* (*n* = 17), *TGFB1* or *TGFBR2* (*n* = 7), and *STAT3* (*n* = 16) are indicated.](jem2051543f01){#fig1}

We tested 16 patients with AD-HIES bearing mutations in *STAT3*. They displayed normal proportions of CCR6-positive CCR4-positive CD4 T cells but low proportions of CCR6-positive CCR4-negative CD4 T cells (Table S2, available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>). These patients had significantly fewer IL-17--positive T cells than controls (P = 9.7 × 10^−7^; [Fig. 1, A and B](#fig1){ref-type="fig"}). However, as observed in patients with IL-12p40 or IL-12Rβ1 deficiency, some AD-HIES patients had normal proportions of IL-17--producing T cells, perhaps reflecting genetic or epigenetic heterogeneity between individuals, residual STAT-3 signaling, or both. In these experimental conditions, the huge variations in IL-17 secretion between healthy controls (from 50 to 5,000 pg/ml), as measured by ELISA, prevented rigorous comparison with the small number of patients studied (unpublished data). We did not assess other potential features of IL-17--producing T cells in the patients studied, such as the production of IL-22, a cytokine produced by Th17 cells in mice ([@bib1]) and humans ([@bib5], [@bib6]), or expression of RORγt, a key transcription factor in mouse ([@bib1]) and human Th17 cells ([@bib11]), as too few blood samples were available. Our results nonetheless suggest that STAT-3 is required for the differentiation of human IL-17--producing T cells in vivo*,* as suggested by flow cytometry analysis on ex vivo--activated T cells. We also assessed the production of IFN-γ in some patients (Fig. S1). The proportion of IFN-γ--producing T cells was found to be lower in patients with mutations in *IRAK4* and *MYD88* (P = 1.2 × 10^−4^), *IL12RB1* and *IL12B* (P = 1.8 × 10^−3^), or *STAT3* (P = 8 × 10^−4^), but not in patients with mutations in *TGFB1* or *TGFBR2* (P = 0.11).

No consensus has yet been reached on how to best induce the differentiation of human IL-17 T cells from naive CD4 precursors in vitro ([@bib5]--[@bib8], [@bib11]--[@bib13]), and only small amounts of blood from a limited number of blood samples from our patients were available. We therefore tried to induce specific IL-17 memory T cell responses using the cytokines shown to be critical for this lineage in the mouse. We evaluated IL-17 production by populations of T cell blasts expanded in vitro from PBMCs. All patients studied, in particular STAT-3--deficient patients, displayed normal proportions of CD4 and CD8 T cells (Table S3, available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>). We incubated nonadherent PBMCs from controls with OKT3 for 5 d, alone or in the presence of IL-23, IL-1β, TGF-β, or IL-6, or a combination of these four cytokines, and then activated them with PMA-ionomycin. We did not assess the development of antigen-specific IL-17--producing T cells. There were no IL-17--positive T cells in any control or in any set of experimental conditions in the absence of activation with PMA-ionomycin, as shown by flow cytometry (unpublished data). In the absence of cytokine stimulation, the percentage of IL-17--positive T cells found in healthy controls after stimulation with PMA-ionomycin was highly variable (from 0.12 to 10%; [Fig. 2 A](#fig2){ref-type="fig"}). A statistically significant increase in the number of IL-17--producing T cells was observed after stimulation with IL-23 (P = 7 × 10^−3^) and IL-1β (P = 0.04), but not after stimulation with TGF-β (P = 0.1) or IL-6 (P = 0.3), as shown by paired *t* tests ([Fig. 2](#fig2){ref-type="fig"} and not depicted). This recall-response pattern is consistent with IL-1β and IL-23 playing an important role in maintaining and expanding IL-17 T cell populations in mice ([@bib1]) and humans ([@bib11]--[@bib13]).

![**Identification of IL-17--expressing T cell blasts expanded in vitro.** Intracellular production of IL-17 in T cell blasts activated with PMA-ionomycin for controls (black circles) and patients (red circles), as assessed by flow cytometry. The cells were cultured in different stimulation conditions: OKT3 only (A), or OKT3 with IL-23 (B), IL-1β (C), or IL-23, IL-1β, TGF-β, and IL-6 (D). Each symbol represents a value for an individual control or patient. Horizontal bars represent medians. In controls, stimulation with IL-23 and IL-1β had a significant effect with respect to medium alone (P \< 0.05). The p-values for Wilcoxon tests between each patient group and the control group are indicated. In B and D, the patients circled in blue carry *IL12B* mutations and cannot produce IL-12 and IL-23, but can respond to both cytokines. The p-value of the *IL12B-IL12RB1* group was therefore calculated only with IL-12Rβ1--deficient patients (\*).](jem2051543f02){#fig2}

We then investigated IL-17 production by T cell blasts from various patients in the same experimental conditions. For four patients with IRAK-4 or MyD88 deficiency and impaired responses to IL-1β, the proportion of IL-17--producing cells appeared to be normal in the various experimental conditions, except in response to IL-1β ([Fig. 2](#fig2){ref-type="fig"}). 16 patients with IL-12p40 (*n* = 2) or IL-12Rβ1 (*n* = 14) deficiency were found to have much smaller proportions of IL-17--producing T cells in the absence of cytokine stimulation (P = 7 × 10^−5^; [Fig. 2 A](#fig2){ref-type="fig"}). The two IL-12p40--deficient patients, unlike the IL-12Rβ1--deficient patients (P = 5 × 10^−5^), apparently responded to IL-23 in these conditions ([Fig. 2 B](#fig2){ref-type="fig"}). These data suggest that IL-23 makes a major contribution to the expansion of the IL-17 T cell population in this assay. However, patients bearing specific IL-23(R) mutations would be required to rigorously test this hypothesis. We then tested seven patients with mutations associated with mildly enhanced TGF-β responses and found no significant differences from controls in the four conditions tested ([Fig. 2](#fig2){ref-type="fig"}).

In contrast, 14 patients with mutations in *STAT3* had almost no detectable IL-17--producing T cells in any of the four conditions tested (P = 3.2 × 10^−8^, 4.9 × 10^−9^, 1.9 × 10^−9^, and 3.6 × 10^−9^, respectively; [Fig. 2](#fig2){ref-type="fig"}). This phenotype was clearly more pronounced than that observed with cells from IL-12p40-- and IL-12Rβ1--deficient patients, as the almost complete lack of IL-17--positive T cells was not complemented by IL-23, IL-1β, or a combination of the four cytokines. T cells from the 11 patients with *STAT3* mutations studied proliferated normally in these conditions. Our results demonstrate that STAT-3 is required for the expansion of IL-17--producing T cell blasts, at least in these experimental conditions. In these conditions, all the groups of patients studied had fewer IFN-γ--producing cells than controls (Fig. S2, available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>).

Finally, we assessed the secretion of IL-17, IL-22, and IFN-γ by T cell blasts from controls and patients, with or without activation with PMA-ionomycin, as measured by ELISA ([Fig. 3](#fig3){ref-type="fig"}; and Figs. S3 and S4, available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>). Control T cell blasts cultured without recombinant cytokine produced detectable amounts of IL-17 in the absence of activation by PMA-ionomycin (mean = 137 ± 149 pg/ml; [Fig. 3 A](#fig3){ref-type="fig"}). The amounts of IL-17 secreted increased significantly (P = 3 × 10^−4^) upon activation with PMA-ionomycin (mean = 7,338 ± 11,134 pg/ml). However, considerable interindividual variability was observed in both sets of experimental conditions. The addition of IL-23, IL-1β, or a combination of IL-23, IL-1β, TGF-β, and IL-6 significantly increased the amounts of secreted IL-17 in the absence of activation with PMA-ionomycin (P = 10^−4^ and 8 × 10^−4^, and P \< 10^−4^, respectively; [Fig. 3, B--D](#fig3){ref-type="fig"}). Upon PMA-ionomycin activation, only IL-1β significantly increased the amount of IL-17 secretion (P = 0.04). Four patients with IRAK-4 or MyD88 deficiency were tested. They displayed low levels of IL-17 secretion in the absence of activation with PMA-ionomycin in the four sets of conditions tested (P = 4 × 10^−3^, 10^−5^, 10^−4^, and 8 × 10^−4^, respectively; [Fig. 3](#fig3){ref-type="fig"}). Upon PMA-ionomycin activation, the level of IL-17 secretion is not significantly different from the controls, except in the presence of IL-1β (P = 0.04; [Fig. 3](#fig3){ref-type="fig"}). These results suggest that the Toll/IL-1R signaling pathway, and possibly the IL-1R pathway, may be involved in the secretion of IL-17 in T cell blasts. These patients produced amounts of IL-22 that were similar to the controls (Fig. S3).

![**IL-17 secretion by T cell blasts expanded in vitro.** Secretion of IL-17 by T cell blasts from controls (black circles) and patients (red circles), as measured by ELISA. Open circles represent values in the absence of stimulation, and closed circles correspond to values obtained after stimulation with PMA-ionomycin. Different stimulation conditions are shown: OKT3 only (A), or OKT3 with IL-23 (B), IL-1β (C), or IL-23, IL-1β, TGF-β, and IL-6 (D). Each symbol corresponds to a value obtained from an individual. Horizontal bars represent medians. The p-values for Wilcoxon tests between each patient group and the control group, either unstimulated or stimulated with PMA-ionomycin, are indicated. In B and D, patients circled in blue carry *IL12B* mutations and cannot produce IL-12 and IL-23, but can respond to both cytokines. The p-values of the *IL12B-IL12RB1* group were therefore calculated only with IL-12Rβ1--deficient patients (\*).](jem2051543f03){#fig3}

T cell blasts from the 13 IL-12p40-- or IL-12Rβ1--deficient patients tested secreted normal amounts of IL-17 in the absence of cytokine stimulation ([Fig. 3 A](#fig3){ref-type="fig"}). The 10 patients tested produced normal amounts of IL-17 in the presence of IL-1β ([Fig. 3 C](#fig3){ref-type="fig"}). In the presence of the four cytokines, patients with IL-12Rβ1 deficiency did not secrete normal amounts of IL-17 without (P = 2 × 10^−3^) or with (P = 10^−3^) PMA-ionomycin stimulation ([Fig. 3 D](#fig3){ref-type="fig"}). In all culture conditions, cells from patients with *IL12B* and *IL12RB1* mutations secreted less IL-22 than control cells (Fig. S3). T cell blasts from all patients with mutations in the TGF-β pathway secreted normal amounts of IL-17, whereas T cell blasts from all patients with STAT-3 deficiency secreted much smaller amounts of IL-17 (P = 8 × 10^−6^, 9 × 10^−7^, 9 × 10^−11^, 2 × 10^−7^, 10^−8^, 3 × 10^−7^, 4 × 10^−9^, and 3 × 10^−6^, respectively) and IL-22 in all experimental conditions ([Fig. 3](#fig3){ref-type="fig"} and Fig. S3). These data indicate that STAT-3 is required for the maintenance and expansion of IL-17--secreting human T cell blasts and for the secretion of IL-22 by human T cell blasts, at least in these experimental conditions.

Patients with STAT-3 deficiency had the most severe IL-17 phenotype of all the patients tested, with a profound impairment of IL-17 production by T cells ex vivo and T cell blasts in vitro. This observation is consistent with findings for STAT-3--deficient mice ([@bib1], [@bib21]--[@bib24]) and a recent report in humans ([@bib25]). Impaired IL-6 signaling may be the key factor involved, as suggested by the results obtained for IL-6--deficient mice ([@bib1], [@bib26], [@bib27]). However, STAT-3 is also involved in other relevant pathways, including the IL-21 and IL-23 pathways. Our data for IL-12p40-- and IL-12Rβ1--deficient cells suggest that IL-23 is required for the optimal development of IL-17--producing T cells. IL-23 is probably the only cytokine involved, as the patients also lacked IL-12 responses, which might be expected to enhance the development of this subset ([@bib1]). This is consistent with the mouse model, in which IL-23 is required for the maintenance and expansion of these cells ([@bib1], [@bib28], [@bib29]), and with the results of previous human studies based on the use of recombinant cytokines ([@bib5]--[@bib8], [@bib11]--[@bib13]). In contrast, our findings for IRAK-4-- and MyD88-deficient cells do not support the notion that IL-1β (or any of the IL-1Rs and TLRs other than, possibly, TLR3 and TLR4) is essential for the development of human IL-17--producing T cells ([@bib5], [@bib6]), consistent with the phenotype of IL-1--deficient mice ([@bib1]). Finally, the paradoxical suggestion that TGF-β may have no effect or may even inhibit the development of human IL-17--producing T cells ([@bib5]--[@bib8]) was neither supported nor disproved by our data for patients with mildly enhanced TGF-β responses ([@bib1]).

Does our report provide any clues to the possible function of IL-17 in host defense? The mouse Th17 subset plays a key role in mucosal defense ([@bib30]). IL-23-- and IL-17--deficient mice are vulnerable to *Klebsiella* ([@bib31], [@bib32]). This may account for the greater susceptibility of IL-12p40-- and IL-12Rβ1--deficient patients than of IFN-γR--deficient patients to both *Klebsiella* (Levin, M., and S. Pedraza, personal communication; Table S1) and the related *Salmonella* ([@bib19]). However, neither *Klebsiella* nor *Salmonella* is commonly found as a pathogen in STAT-3--deficient patients despite the apparently greater defect of these patients in terms of IL-17--producing T cell development ([@bib17], [@bib18]). Mice with impaired IL-17 immunity are also susceptible to *Candida* ([@bib33]--[@bib35]). This may account for the peripheral candidiasis commonly seen in STAT-3--deficient patients. Interestingly, although most IL-12p40-- and IL-12Rβ1--deficient patients are not susceptible to *Candida* ([@bib19]), some present with peripheral candidiasis (unpublished data). Mycobacterial disease is exceedingly rare in STAT-3--deficient patients, but not in IL-12p40-- and IL-12Rβ1--deficient patients, in whom it results from impaired IFN-γ immunity, which is consistent with the redundancy of IL-17 in mouse primary immunity to mycobacteria ([@bib36], [@bib37]). Staphylococcal disease is the main infection seen in STAT-3--deficient patients. Mouse IL-17 seems to be involved in immunity to *Staphylococcus* ([@bib38]). However, both IL-12p40-- and IL-12Rβ1--deficient patients are normally resistant to *Staphylococcus*. The function of human IL-17 and related cytokines in host defense therefore remains unknown. The genetic dissection of human infectious diseases should help us to attribute a function to this important cytokine in natura ([@bib39], [@bib40]).

MATERIALS AND METHODS
=====================

Patients and controls.
----------------------

55 healthy, unrelated individuals of various ages from 12 countries (Argentina, Canada, Cuba, France, Germany, Israel, Portugal, Spain, Switzerland, Turkey, UK, and USA) were tested as controls. We also investigated 50 patients with mutations in *IRAK4*, *MYD88*, *IL12B*, *IL12RB1*, *TGFB1*, *TGFBR1*, *TGFBR2*, or *STAT3* (Table S1). Our study was conducted in accordance with the Helsinki Declaration, with informed consent obtained from each patient or the patient\'s family, as requested and approved by the institutional review board of the Necker Medical School.

Purification and activation of nonadherent PBMCs.
-------------------------------------------------

PBMCs were purified by centrifugation on a gradient (Ficoll-Paque PLUS; GE Healthcare) and resuspended in 10% FBS in RPMI (RPMI-10% FBS; Invitrogen). Adherent monocytes were removed by plating PBMCs in a 75-cm^2^ horizontal culture flask and incubating them for 2--3 h at 37°C in an atmosphere containing 5% CO~2~. The nonadherent cells were washed in RPMI and counted with a counter (Vi-Cell XR; Beckman Coulter). For flow cytometry, we distributed 5 × 10^6^ cells in 5 ml RPMI-10% FBS in two 25-cm^2^ vertical culture flasks. One flask was stimulated with 40 ng/ml PMA (Sigma-Aldrich) and 10^−5^ M ionomycin (Sigma-Aldrich). All cells were treated with 1 μl/ml Golgiplug (BD Biosciences), a secretion inhibitor. The flasks were incubated for 12 h at 37°C under an atmosphere containing 5% CO~2~. For ELISA, a 200-μl aliquot of cells at a concentration of 2.5 × 10^6^ cells/ml in RPMI-10% FBS was dispensed into each well of a 96-well plate. The cells were or were not activated with 40 ng/ml PMA and 10^−5^ M ionomycin. Supernatants were collected after 48 h of incubation at 37°C under an atmosphere containing 5% CO~2~.

Expansion and activation of T cell blasts.
------------------------------------------

Nonadherent PBMCs were dispensed into 24-well plates at a density of 2.5 × 10^6^ cells/ml in RPMI-10% FBS. All cells were activated with 2 μg/ml of an antibody against CD3 (Orthoclone OKT3; Janssen-Cilag) alone, or together with 5 ng/ml TGF-β1 (240-B; R&D Systems), 20 ng/ml IL-23 (1290-IL; R&D Systems), 25 ng/ml IL-6 (206-IL; R&D Systems), 10 ng/ml IL-1β (201-LB; R&D Systems), or combinations of these four cytokines. Plates were incubated at 37°C under an atmosphere containing 5% CO~2~ for 3 d. The cells in each well were restimulated using the same activation conditions, except that the antibody against CD3 was replaced by 40 IU/ml IL-2 (Proleukin i.v.; Chiron). 1 ml of each appropriate medium was added, and we gently passed the culture up and down through a pipette to break up clumps. The culture in each well was split in two. Flow cytometry was performed on one of the duplicate wells 2 d later. The cells in this well were stimulated by incubation for 12 h with 40 ng/ml PMA and 10^−5^ M ionomycin plus 1 μl/ml Golgiplug at 37°C under an atmosphere containing 5% CO~2~. FACS analysis was performed as described in the following section, without extracellular labeling. For ELISA analysis, cultures were allowed to differentiate under various conditions for 6 d and were then diluted 1:2 in RPMI-10% FBS supplemented with 40 IU/ml IL-2. 200 μl of cells in a 96-well plate were activated with 40 ng/ml PMA and 10^−5^ M ionomycin, or left unactivated. Supernatants were collected after 48 h of incubation at 37°C under an atmosphere containing 5% CO~2~.

Flow cytometry.
---------------

Cells were washed in cold PBS and dispensed into a 96-well plate for labeling. Extracellular labeling (for the ex vivo study only) was achieved by incubating the cells with 3 μl CD3-PECy5 in 50 μl PBS-2% FBS (BD Biosciences) for 20 min on ice. The cells were washed twice with cold PBS-2% FBS. They were fixed by incubation with 100 μl BD Cytofix (BD Biosciences) for 30 min on ice and washed twice with BD Cytoperm (BD Biosciences), with a 10-min incubation period in BD Cytoperm on ice for the first wash. Cells were then incubated for 1 h on ice with IL-17--Alexa Fluor 488 (eBioscience) or IFN-γ--PE (BD Biosciences) at a dilution of 3 μl of antibody in 50 μl BD Cytoperm. Cells were washed twice with BD Cytoperm and analyzed with a FACScan machine and CellQuest software (both from Becton Dickinson).

Determination of cytokine levels by ELISA.
------------------------------------------

IL-17, IL-22, and IFN-γ levels were determined by ELISA. We used the capture antibodies, detection antibodies, and standards supplied in the kits for IL-17 and IL-22 (Duoset; R&D Systems) and in the kit for IFN-γ (Sanquin), diluted in HPE dilution buffer (Sanquin). Milk was used for blocking, and antibody binding was detected with streptavidin poly--horseradish peroxidase (Sanquin) and TMB microwell peroxidase substrate (KPL). The reaction was stopped by adding 1.8 M H~2~SO~4~. Optical density was determined with a microplate reader (MRX; Thermolab Systems).

Statistical analysis.
---------------------

We first assessed differences between controls and patients (when there were more than two patients) for (a) the percentage of circulating IL-17--producing T cells, (b) the percentage of IL-17--positive T cells in vitro, and (c) the level of IL-17 production in various stimulation conditions, as assessed by ELISA. As the distribution of these three variables could not be assumed to be normal and some of the patient groups examined were very small, we used the nonparametric Wilcoxon exact test, as implemented in the NPAR1WAY module of SAS software (version 9.1; SAS Institute). A second set of tests was performed on controls only to assess the effects of different stimulation conditions on (a) the percentage of IL-17--positive T cells in vitro and (b) the level of IL-17 production, as assessed by ELISA. We used a strategy of matching, with paired *t* tests performed with the TTEST procedure of SAS software (version 9.1) to investigate the correlation between observations for different controls. For all analyses, P \< 0.05 was considered statistically significant.

Online supplemental material.
-----------------------------

Fig. S1 shows the percentage of CD3-positive IFN-γ--positive cells, as determined by flow cytometry of nonadherent PBMCs activated with PMA-ionomycin from controls and patients. Fig. S2 shows intracellular IFN-γ production in T cell blasts activated with PMA-ionomycin from controls and patients in the various culture conditions, as assessed by flow cytometry. Fig. S3 shows the secretion of IL-22 by T cell blasts from controls and patients in the various culture conditions, as measured by ELISA. Fig. S4 shows the secretion of IFN-γ by T cell blasts from controls and patients in the various culture conditions, as measured by ELISA. Table S1 shows the genetic and clinical features of the patients studied. Table S2 shows the proportions of CCR6-positive CD4 T cells in controls and STAT-3--deficient patients. Table S3 shows the proportions of CD4 and CD8 T cells in patients. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20080321/DC1>.
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